Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 May 2017 According to an Immune Therapeutics media release, the company is ready to submit a New Drug Application (NDA) to the Directorate of Pharmacy and Medicines. The application will include results of four phase II clinical trials and one bridging trial clinical trial.
26 Oct 2016 According to Immune Therapeutics media release, the Ministry of Health and Prevention Division of Pharmacy in the Republic of Senegal (the "Ministry of Health") accepted for review the Company's New Drug Applications ("NDAs") for LodonalTM as a stand alone or adjunct therapy non-toxic in the treatment of HIV/AIDS, cancer and as an immune booster.
18 Aug 2010 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com